Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Target-Guided Personalized Chemotherapy in Metastatic Colorectal Cancer
NCT01453257Phase 2Completed
- Sponsor
- HM Hospitales
- Start
- Oct 2009
- Primary completion
- Oct 2011
- Modality
- Antibody Conjugates, Monoclonal Antibodies, DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, oxaliplatin, irinotecan, capecitabine, cetuximab and 1 more in metastatic colorectal cancer (mCRC), sponsored by HM Hospitales. Primary endpoint: Progression Free Survival at 12 months. Started Oct 2009; status: completed.
02
Drugs
fluorouraciloxaliplatinirinotecancapecitabinecetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01453257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01453257.